13F Pro13F Pro

Ishara Investments LP

Institutional InvestorSimilar funds →SEC EDGAR: CIK 2111609
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare100.0%$136.1M

AUM History

13fpro.ai/research/fund/ishara-investments-lp-2111609

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/ishara-investments-lp-2111609

Ishara Investments LP 13F holdings — Q2 2026

$136.1M portfolio (+28.9% QoQ) · 41 holdings · Q2 2026 13F · top 10 are 51% of the stock portfolio

All holdings — Ishara Investments LP (Q2 2026)

41 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
ANNX$ANNXAnnexon, Inc.$4.7M+371%
TVTX$TVTXTravere Therapeutics, Inc.$4.7M-26%
TNXP$TNXPTonix Pharmaceuticals Holding Corp.$4.3MNew
BBIO$BBIOBridgeBio Pharma, Inc.$4.3MNew
AXSM$AXSMAxsome Therapeutics, Inc.$4.0M-60%
CTNM$CTNMContineum Therapeutics, Inc.$3.4M+44%
LXRX$LXRXLEXICON PHARMACEUTICALS, INC.$3.1M+41%
KURA$KURAKura Oncology, Inc.$3.0MNew
DBVT$DBVTDBV Technologies S.A.adr$3.0M+80%
GMAB$GMABGENMAB A/Sadr$2.8M+25%
CYTK$CYTKCYTOKINETICS INC$2.8MNew
MLYS$MLYSMineralys Therapeutics, Inc.$2.8M+25%
SLN$SLNSilence Therapeutics plcadr$2.4M-61%
NUVB$NUVBNuvation Bio Inc.$2.1MNew
WVE$WVEWave Life Sciences, Inc.$1.9MNew

What changed in Q2 2026

Against the previous quarter's 13F: 16 new, 13 added to, 8 trimmed, 12 sold out. Share-count changes; largest moves by dollar size first.

New positions (16)

  • AGIO$AGIOAGIOS PHARMACEUTICALS, INC.$6.1M

    first bought this quarter

  • INSM$INSMINSMED Inc$5.5M

    first bought this quarter

  • CRNX$CRNXCrinetics Pharmaceuticals, Inc.$5.4M

    first bought this quarter

  • TNXP$TNXPTonix Pharmaceuticals Holding Corp.$4.3M

    first bought this quarter

  • BBIO$BBIOBridgeBio Pharma, Inc.$4.3M

    first bought this quarter

  • KURA$KURAKura Oncology, Inc.$3.0M

    first bought this quarter

+10 more in the Excel export

Added to (13)

  • ACAD$ACADACADIA PHARMACEUTICALS INC+233%

    now $10.4M · held 3+ qtrs

  • ANNX$ANNXAnnexon, Inc.+371%

    now $4.7M · held 3+ qtrs

  • BMRN$BMRNBIOMARIN PHARMACEUTICAL INC+75%

    now $8.2M · held 3+ qtrs

  • XERS$XERSXeris Biopharma Holdings, Inc.+20%

    now $9.7M · held 3+ qtrs, 2 adds in a row

  • PCVX$PCVXVaxcyte, Inc.+43%

    now $4.8M · held 3+ qtrs, 2 adds in a row

  • DBVT$DBVTDBV Technologies S.A.+80%

    now $3.0M · held 2 qtrs, 2 adds in a row

+7 more in the Excel export

Trimmed (8)

  • AXSM$AXSMAxsome Therapeutics, Inc.-60%

    now $4.0M · held 2 qtrs

  • SLN$SLNSilence Therapeutics plc-61%

    now $2.4M · held 3+ qtrs, 2 trims in a row

  • VERA$VERAVera Therapeutics, Inc.-88%

    now $440K · held 2 qtrs

  • TVTX$TVTXTravere Therapeutics, Inc.-26%

    now $4.7M · held 2 qtrs

  • SRRK$SRRKScholar Rock Holding Corp-46%

    now $1.7M · held 2 qtrs

  • IMTX$IMTXImmatics N.V.-80%

    now $311K · held 3+ qtrs

+2 more in the Excel export

Sold out (12)

  • PRAX$PRAXPUTPraxis Precision Medicines, Inc.was $6.6M
  • KALV$KALVKalVista Pharmaceuticals, Inc.was $5.6M

    held 1 qtr

  • FOLD$FOLDAMICUS THERAPEUTICS, INC.was $5.3M

    held 2+ qtrs

  • VSTM$VSTMVerastem, Inc.was $4.3M

    held 2+ qtrs

  • ARWR$ARWRARROWHEAD PHARMACEUTICALS, INC.was $3.5M

    held 1 qtr

  • MLTX$MLTXMoonLake Immunotherapeuticswas $3.2M

    held 1 qtr

+6 more in the Excel export

Firm AUM (Form ADV): $259.1M as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Ishara Investments LP has filed, 2 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Ishara Investments?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Ishara Investments's top 20 holdings: 43/100 (our AI quality score, weighted by position size; 15 of the 20 are scored)

Top 10 since filing

-15.8%

Value-weighted move of the 10 largest stock positions

Turnover

43%

Last quarter

Top 10 weight

51%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

0%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q4 2025 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Ishara Investments LP disclosed 41 positions worth $136.1M in its Form 13F-HR for Q2 2026, led by $ACAD (ACADIA PHARMACEUTICALS INC) at 7.6% of the equity portfolio, followed by $XERS and $BMRN. During the quarter the fund opened 16 new positions and exited 12 — including a new stake in $AGIO and a full exit from $PRAX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Ishara Investments LP’s Form 13F-HR filing with the SEC under CIK 2111609.

Funds like this

managers whose biggest positions overlap Ishara Investments's
BAKER BROS. ADVISORS LP$19.96B 13F book · 6 shared top holdingsACADINSMPRAXCRNXFirst Turn Management, LLC$934.72M 13F book · 12 shared top holdingsBBIOINSMPRAXAXSMARMISTICE CAPITAL, LLC$8.17B 13F book · 6 shared top holdingsAGIOTVTXCYTKMLYSBellevue Group AG$4.75B 13F book · 9 shared top holdingsINSMPCVXCRNXBBIODeep Track Capital, LP$6.87B 13F book · 7 shared top holdingsPCVXBMRNAXSMGMABIntegral Health Asset Management, LLC$2.53B 13F book · 9 shared top holdingsINSMAXSMCYTKSRRK

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Ishara Investments LP

13F Pro is an AI hedge fund tracker and stock research platform. For Ishara Investments LP (SEC CIK: 2111609), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Ishara Investments LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.